Barclays analyst Glen Santangelo initiated coverage of Doximity (DOCS) with an Overweight rating and $63 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Nvidia resumed, Palo Alto downgraded: Wall Street’s top analyst calls
- Doximity: Strong Growth Potential and Attractive Valuation Amid Share Price Pullback
- Doximity upgraded to Strong Buy from Outperform at Raymond James
- Doximity initiated with a Market Perform at BMO Capital
- OpenAI Is Considering Expanding into Healthcare